A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.

• Status: Terminated
• Trial end date: 2014-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This Phase II study will evaluate the safety and efficacy of three fluoroquinolone ophthalmic agents to determine the optimal treatment in patients with infectious corneal ulcers.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cornea Consultants Of Nashville
• Collaborators: Bausch & Lomb Incorporated; SCRI Development Innovations, LLC
• Treatments: 7-(3-aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; Besifloxacin; Fluoroquinolones; Gatifloxacin; Moxifloxacin; Norgestimate, ethinyl estradiol drug combination; Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

1. Patients must be between the ages of 18-90 years of age.

2. Patients must be able to understand the nature of this study, give written informed consent prior to study entry, and comply with study requirements.

3. Patients must have a corneal ulcer greater than 2mm but less than 6mm in size.

4. Patients must have corneal ulcer present in only one eye.

5. Patients must agree not to wear contact lenses while on study.

Exclusion Criteria:

1. Patients with multifocal ulcers.

2. Signs of any other viral or fungal infection.

3. Treatment with antibiotics within 14 days of study entry.

4. Treatment with systemic or topical ocular antiviral agents or systemic or topical steroids or topical ocular nonsteroidal anti-inflammatory drugs (NSAIDS) during the prior 14-day period.

5. Known hypersensitivity or allergy to steroids (Loteprednol etabonate) or to any of the ingredients in the three study drugs (Besifloxacin 0.6% or Gatifloxacin 0.5% or Moxifloxacin 0.5%).

6. Contact lens only with no spectacles available.

7. Ocular surgery (including laser surgery) in either eye within 6 weeks prior to entry into this study.

8. Participation in any investigational study within the past 30 days.

9. Pregnant women, minors, or those not able to consent for themselves.